What Can You Expect in 2025?
As GPCR-targeted drug discovery continues to surge across Europe, driven by the commercial success of GLP-1 therapies and a wave of industry investment, biopharma companies are reinvesting in innovative GPCR strategies to expand the druggable landscape. The 2nd Annual GPCR-Targeted Drug Discovery Summit Europe is your chance to explore the latest clinical case studies, de-orphanisation strategies, and the application of AI and ML in structure-based drug design, unlocking previously inaccessible GPCR targets.
Unmissable Event Highlights
Harness AI for Smarter GPCR Discovery
Use machine learning and AI-driven modelling to bridge structural data gaps, reveal new binding sites, prioritise hits more effectively, and design precise therapeutics, turning previously inaccessible GPCRs into promising clinical candidates.
With Expert Insights From:
- Lewis Vidler, Senior Director – Structure-Base- Drug-Design, Eli Lilly
- Irina Tikhonova, Molecular Modelling Reader, Queen’s University Belfast
- Juan-Carlos Mobarec, Head of Computational Structural Biology, AstraZeneca
Innovate with Next-Generation Antibodies
Explore cutting-edge antibody modalities, including depleting antibodies, stabilised active-state agonists, and functional biologics, to expand GPCR therapeutic options and accelerate development of durable, patient-focused treatments.
With Expert Insights From:
- Stephan Schann, Chief Scientific Officer, Domain Therapeutics
- Robin Löving, CSO, Salipro Biotech
- Christel Menet, Chief Scientific Officer, Confo Therapeutics
Unlock Orphan and Challenging GPCRs
Learn how Novartis and Alphamol Science identify potent modulators, uncover novel allosteric sites, and leverage advanced computational methods to bring complex GPCRs from discovery to first-in-class therapeutics addressing unmet medical needs.
With Expert Insights From:
- Shuguang Yuan, Co-founder, Alphamol Science
- Paul Groot-Kormelink, Associate Director in Discovery Sciences, Novartis
- Graeme Milligan, Professor of Biochemistry, University of Glasgow
Revolutionise Structure-Based Design
Apply the latest structural biology tools, from cryo-EM and X-ray crystallography to molecular dynamics, to decode receptor binding, activation, and signalling, enabling design of highly selective GPCR therapeutics.
With Expert Insights From:
- Dietmar Weichert, Principal Scientist, Boehringer Ingelheim
- Laia Malet Sanz, Director - Medicinal Chemistry, OMass Therapeutics
Explore the Full Event Guide
- 60+ Attendees
- 18+ Speakers
- 16+ Data-driven Presentations
- 2 Interactive Workshops
- 1 Scientific Poster Session
Attending Companies Include
Explore the Agenda
Hear the latest industry trends and gain exclusive insights during our packed agenda, interactive roundtables and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.